# A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cance

Source: https://onco.cc/trials/nct06822543/  
OnCo record `nct06822543` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pembrolizumab, datopotamab deruxtecan and carboplatin in lung cancer, run by Latin American Cooperative Oncology Group, now recruiting.

## Summary

A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) is a phase 2, interventional study registered as NCT06822543 by Latin American Cooperative Oncology Group, with a registry enrolment figure of 46 participants, started 2025-09-12 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pembrolizumab; Datopotamab deruxtecan; Carboplatin. Conditions listed: Lung Cancer; Non Small Cell Lung Cancer; Brain Metastases. Primary outcome: Confirmed Intracranial Objective Response Rate (iORR) as Measured by the RANO-BM Criteria. Lung eligibility wording from the registry: "\- Male/female participants who are at least 18 years of age on the day of signing informed consent with a histologically confirmed diagnosis of NSCLC will be enrolled in this study". Sites: Brazil. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Also known as: TROPICAL-1
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06822543
- Phase: 2
- Setting: A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
- Sponsor: Latin American Cooperative Oncology Group
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06822543: https://clinicaltrials.gov/study/NCT06822543

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06822543.json